Time-dependent systemic hemostatic effects of fibrin monomer in controlled liver injury in the experiment
- Authors: Vdovin VM1,2, Momot AP2,3, Orekhov DA4, Tolstokorov IG5, Shevchenko VO5, Krasyukova VO1, Shakhmatov II1,2, Lycheva NA1,2, Belozerskaya GG6
-
Affiliations:
- Altai State Medical University
- National Research Institute of Physiology and Basic Medicine
- National Research Center for Hematology, Altai Branch
- Altai Regional Cardiology Health Center
- Consulting Diagnostic Center «Dobryy Doktor» Ltd
- National Research Center for Hematology
- Issue: Vol 100, No 2 (2019)
- Pages: 257-263
- Section: Experimental medicine
- URL: https://journals.rcsi.science/kazanmedj/article/view/11536
- DOI: https://doi.org/10.17816/KMJ2019-257
- ID: 11536
Cite item
Full Text
Abstract
Aim. To evaluate the hemostatic effect of fibrin monomer after its intravenous administration at different time periods in experimental trauma.
Methods. In the experiments, in a placebo-controlled study, hemostatic and hemostasiological effects of systemic use of fibrin monomer were studied at different time periods after its administration (in 5 min, 1 h and 3 h) in 97 male rabbits of the Chinchilla breed in the controlled liver injury model.
Results. A pronounced hemostatic effect was demonstrated for fibrin monomer used at a dose of 0.25 mg/kg demonstrated by a 6.3-fold decrease of blood loss volume (% of circulating blood volume) compared to placebo on the background of the intravenous preventive fibrin monomer administration 1 hour prior to controlled liver injury. Fibrin monomer administration at a stated dose was not accompanied by significant changes in haemocoagulative parameters including measurement of platelet count, activated partial thromboplastin time, prothrombin time, thrombin time, echitox time, fibrinogen concentration, level of soluble fibrin monomer complexes, D-dimer content, and antithrombin III activity. The effect of fibrin monomer is probably realized through some effectors, the nature of which has not yet been studied. The obtained results allow choosing the optimal interval between intravenous administrations of fibrin monomer and controlled liver injury for further study of the mechanisms of its hemostatic action.
Conclusion. Fibrin monomer in small doses (0.25 mg/kg) is able to exert a pronounced hemostatic effect with its systemic administration 1 hour prior to the injury without significant changes in haemocoagulative parameters.
Full Text
##article.viewOnOriginalSite##About the authors
V M Vdovin
Altai State Medical University; National Research Institute of Physiology and Basic Medicine
Author for correspondence.
Email: erytrab@gmail.com
Barnaul, Russia; Novosibirsk, Russia
A P Momot
National Research Institute of Physiology and Basic Medicine; National Research Center for Hematology, Altai Branch
Email: erytrab@gmail.com
Novosibirsk, Russia; Barnaul, Russia
D A Orekhov
Altai Regional Cardiology Health Center
Email: erytrab@gmail.com
Barnaul, Russia
I G Tolstokorov
Consulting Diagnostic Center «Dobryy Doktor» Ltd
Email: erytrab@gmail.com
Barnaul; Russia
V O Shevchenko
Consulting Diagnostic Center «Dobryy Doktor» Ltd
Email: erytrab@gmail.com
Barnaul; Russia
V O Krasyukova
Altai State Medical University
Email: erytrab@gmail.com
Barnaul, Russia
I I Shakhmatov
Altai State Medical University; National Research Institute of Physiology and Basic Medicine
Email: erytrab@gmail.com
Barnaul, Russia; Novosibirsk, Russia
N A Lycheva
Altai State Medical University; National Research Institute of Physiology and Basic Medicine
Email: erytrab@gmail.com
Barnaul, Russia; Novosibirsk, Russia
G G Belozerskaya
National Research Center for Hematology
Email: erytrab@gmail.com
Moscow, Russia
References
- Rossaint R., Bouillon B., Cerny V. et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit. Care. 2016; 12 (20): 100. doi: 10.1186/s13054-016-1265-x.
- Cap A., Hunt B.J. The pathogenesis of traumatic coagulopathy. Anaesthesia. 2015; 70 (1): 96–101. doi: 10.1111/anae.12914.
- Levi M. Management of bleeding in patients treated with direct oral anticoagulants. Crit. Care. 2016; 20: 249. doi: 10.1186/s13054-016-1413-3.
- Damage Control Resuscitation at Level IIb/III Treatment Facilities. Joint theater trauma system clinical practice guideline. Feb. 2013. http://9thcall.ru/wp-content/uploads/2019/02/Management-of-crush-syndrome-under-prolonged-field-care.pdf (access date: 05.12.2018).
- Hayes B.D., Winters M.E., Rosenbaum S.B. et al. What is the role of reversal agents in the management of emergency department patients with dabigatran-associated hemorrhage? J. Emerg. Med. 2018; 54 (4): 571–575. doi: 10.1016/j.jemermed.2017.12.061.
- Lambourne M.D., Eltringham-Smith L.J., Gataiance S. et al. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J. Thromb. Haemost. 2012; 10 (9): 1830–1840. doi: 10.1111/j.1538-7836.2012.04863.x.
- Kudryashov B.A., Molchanova L.V., Kalishevskaya T.M. et al. About the functional state of the anticoagulation system during intravenous administration of fibrin monomer. Voprosy meditsinskoy khimii. 1969; 15 (5): 483–486. (In Russ.)
- Zubairov D.M. Molekulyarnye osnovy svertyvaniya krovi i tromboobrazovaniya. (Molecular basis of blood clotting and thrombus formation.) Kazan: Fen. 2000; 368 р. (In Russ.)
- Weisel J.W., Litvinov R.I. Fibrin formation, structure, and properties. In: Fibrous proteins: structures and mechanisms. D.A.D. Parry, J.M. Squire eds. Subcellular Biochemistry. 2017; 82: 405–456. doi: 10.1007/978-3-319-
- -0_13.
- Momot A.P., Vdovin V.M., Tolstokorov I.G. et al. Method for preventing intraoperative bleeding caused by preoperative introduction of heparin. Patent for invention RF №2544805. Bulletin issued on 20.03.2015. (In Russ.)
- Momot A.P., Shakhmatov I.I., Lomaev I.S., Terekhov S.S. A method for commercial production of fibrin monomer from blood plasma. Patent for invention RF №2522237. Bulletin issued on 15.05.2014. (In Russ.)
- Khabriev R.Yu. Rukovodstvo po ehksperimentalnomu (doklinicheskomu) izucheniyu novykh farmakologicheskikh veshchestv. (Guidelines for experimental (preclinical) study of new pharmacological substances.) 2-nd ed., Moscow: Meditsina. 2005; 828 p. (In Russ.)
- Barkagan Z.S., Momot A.P. Diagnostika i kontroliruemaya terapiya narushenij gemostaza. (Diagnostics and controlled therapy of the hemostatic system.) Moscow: N`yudiamed. 2008; 283 p. (In Russ.)
- Soboleva I.V., Subkhanukulova F.B., Minnebaev M.M., Zubairov D.M. Circulation of soluble fibrin monomer in the body. Voprosy meditsinskoy khimii. 1978; 24 (3): 358–361. (In Russ.)
- Byshevskiy A.Sh., Galyan S.L., Kalinin E.P. et al. About regulation of non-enzymatic stage of blood coagulation (autopolymerization and aggregation of fibrin). Tromboz, gemostaz i reologiya. 2012; (1): 27–46. (In Russ.)